Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as...
Change of Director's Interest Notice
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Notification of cessation of securities - PER
- Percheron receives $0.70m R&D Tax Incentive Rebate
- Trading Halt
- Vanderbilt Health to conduct clinical trial of HMBD-002
- Appendix 4E and Annual Report
Later from Percheron Therapeutics
- Transitional appointment of Executive Director
- Initial Director's Interest Notice
- Proposed issue of securities - PER
- Percheron raises $2.3m to fully fund clinical trial in AML
- Percheron Therapeutics Limited Corporate Presentation
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics